kostaive
Generic: ARCT-154·Code: ARCT-154, ARCT-2301, ARCT-2303
kostaive: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | Approved |
FDA Decisions
Frequently asked questions
Who is developing kostaive?
kostaive is being developed by Arcturus Therapeutics Holdings Inc..
What is kostaive's latest FDA decision?
The most recent tracked FDA decision for kostaive is FDA_Meeting for FDA requested delay of the planned BLA submission to provide additional advice., dated September 5, 2025.
Get deeper analysis on kostaive
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis